Paxalisib it broadly recognised as remarkable Increasing efficacy by +60% on the current standard of care... in GBM the primary condition of focus
Kazia identified a shelved molecule at the storied cancer drug development company, Genentech.
In fact, Genentech has been so successful at therapeutic development, when Roche Holdings took them over, it chose to leave it completely intact so as not to destroy Genentech’s culture of success.
Kazia felt there was a lot to like about the drug, named GDC-0084 at the time, and we concurred.
Specifically:
The science behind paxalisib was outstanding,
- Forums
- ASX - By Stock
- Cantrixil Final Phase 1 Data
Paxalisib it broadly recognised as remarkable Increasing...
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)